ALLO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.30%

Insider Buying (Last 12 Months): $4,999,997.30

Insider Selling (Last 12 Months): $274,040.02

Allogene Therapeutics Insider Trading History Chart

Allogene Therapeutics Share Price & Price History

^$1.61

▲ +0.02 (1.26%)

As of 04/23/2025 05:00 PM ET

Days: 30 | 90 | 365

Allogene Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/21/2025	Annie Yoshiyama	SVP	Sell	9,601	$1.41	$13,537.41	130,663
3/14/2025	Benjamin Machinas Beneski	SVP	Sell	5,488	$1.98	$10,866.24	218,507
3/14/2025	David D Chang	CEO	Sell	46,668	$1.96	$91,469.28	5,276,569
2/3/2025	Earl Martin Douglas	SVP	Sell	6,404	$1.71	$10,950.84	587,848
2/3/2025	Geoffrey M Parker	CFO	Sell	4,361	$1.73	$7,544.53	1,301,540
2/3/2025	Timothy L Moore	Insider	Sell	14,746	$1.71	$25,215.66	250,713
1/21/2025	Zachary Roberts	EVP	Sell	27,199	$1.78	$48,414.22	488,054
12/9/2024	Deborah M Messemer	Director	Sell	9,136	$2.18	$19,916.48	157,629
12/5/2024	Franz B Humer	Director	Sell	9,221	$2.16	$19,917.36	307,507
5/30/2024	Franz B Humer	Director	Sell	11,200	$2.34	$26,208.00	255,253
5/16/2024	Arie Belldegrun	Director	Buy	1,724,137	$2.90	$4,999,997.30	1,724,137
1/30/2024	Geoffrey M Parker	CFO	Buy	190	$3.60	$684.00	819,590
12/18/2023	Deborah M Messemer	Director	Sell	18,640	$2.70	$50,328.00	62,456
8/7/2023	Stephen Mayo	Director	Sell	10,000	$4.29	$42,900.00	25,328
2/13/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$6.85	$20,550.00	577,677
1/17/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$7.04	$21,120.00	580,677
12/15/2022	Veer Bhavnagri	General Counsel	Sell	5,602	$7.53	$42,183.06	583,677
8/11/2022	Owen N. Witte	Director	Sell	10,000	$16.50	$165,000.00	223,271
8/2/2022	Rafael Amado	CMO	Sell	2,000	$11.97	$23,940.00	540,257
7/5/2022	Rafael Amado	CMO	Sell	2,000	$11.44	$22,880.00	542,257
6/22/2022	Owen N. Witte	Director	Sell	10,000	$11.76	$117,600.00	233,271
6/21/2022	Rafael Amado	CMO	Sell	2,000	$11.18	$22,360.00	544,257
5/19/2022	Rafael Amado	CMO	Sell	11,500	$7.40	$85,100.00	546,257

SEC Filings (Institutional Ownership Changes) for Allogene Therapeutics (NASDAQ:ALLO)

83.63% of Allogene Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Allogene Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/17/2025	Exchange Traded Concepts LLC	68,858	$0.10M	0.0%	+13.5%	0.032%
4/16/2025	Wealth Enhancement Advisory Services LLC	19,260	$28K	0.0%	N/A	0.009%
4/8/2025	Rhumbline Advisers	183,708	$0.27M	0.0%	-4.2%	0.085%
3/18/2025	California State Teachers Retirement System	135,554	$0.29M	0.0%	+6.0%	0.065%
2/18/2025	Navalign LLC	59,865	$0.13M	0.0%	-20.6%	0.029%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	270,559	$0.58M	0.0%	+18.2%	0.129%
2/17/2025	Squarepoint Ops LLC	20,345	$43K	0.0%	-89.2%	0.010%
2/17/2025	Two Sigma Advisers LP	2,702,200	$5.76M	0.0%	+12.1%	1.289%
2/17/2025	Two Sigma Investments LP	2,712,139	$5.78M	0.0%	-3.1%	1.294%
2/17/2025	Tidal Investments LLC	135,952	$0.29M	0.0%	-4.8%	0.065%
2/17/2025	Rafferty Asset Management LLC	367,445	$0.78M	0.0%	+15.9%	0.175%
2/17/2025	Raiffeisen Bank International AG	430,000	$0.90M	0.0%	N/A	0.205%
2/17/2025	ProShare Advisors LLC	46,082	$98K	0.0%	+25.6%	0.022%
2/17/2025	Patient Square Capital LP	1,489,909	$3.17M	1.2%	N/A	0.711%
2/17/2025	Nuveen Asset Management LLC	300,871	$0.64M	0.0%	+18.3%	0.143%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	305,895	$0.65M	0.0%	+23.6%	0.146%
2/17/2025	Graham Capital Management L.P.	41,737	$89K	0.0%	N/A	0.020%
2/17/2025	Coastal Bridge Advisors LLC	221,059	$0.47M	0.1%	-45.5%	0.105%
2/17/2025	D. E. Shaw & Co. Inc.	54,517	$0.12M	0.0%	-39.6%	0.026%
2/17/2025	DAFNA Capital Management LLC	1,240,118	$2.64M	0.7%	+18.1%	0.591%
2/17/2025	Caption Management LLC	15,000	$32K	0.0%	N/A	0.007%
2/17/2025	Brevan Howard Capital Management LP	87,573	$0.19M	0.0%	+38.9%	0.042%
2/17/2025	Caxton Associates LP	206,380	$0.44M	0.0%	-14.8%	0.098%
2/17/2025	Bank of America Corp DE	1,163,743	$2.48M	0.0%	+99.3%	0.555%
2/17/2025	BNP Paribas Financial Markets	849,658	$1.81M	0.0%	+1,732.2%	0.405%
2/17/2025	Ameriprise Financial Inc.	201,943	$0.43M	0.0%	+14.0%	0.096%
2/14/2025	Jane Street Group LLC	164,523	$0.35M	0.0%	-63.5%	0.078%
2/14/2025	Foresite Capital Management VI LLC	3,448,275	$7.35M	3.3%	N/A	1.645%
2/14/2025	Northern Trust Corp	1,305,232	$2.78M	0.0%	+4.5%	0.623%
2/14/2025	Lynx1 Capital Management LP	10,874,723	$23.16M	8.7%	+75.3%	5.187%
2/14/2025	Susquehanna Fundamental Investments LLC	376,661	$0.80M	0.0%	N/A	0.180%
2/14/2025	Syon Capital LLC	18,351	$39K	0.0%	N/A	0.009%
2/14/2025	Price T Rowe Associates Inc. MD	4,485,572	$9.56M	0.0%	-7.3%	2.139%
2/14/2025	Hsbc Holdings PLC	69,155	$0.15M	0.0%	+32.0%	0.033%
2/14/2025	MetLife Investment Management LLC	38,020	$81K	0.0%	-28.5%	0.018%
2/14/2025	Dimensional Fund Advisors LP	3,561,626	$7.59M	0.0%	+30.4%	1.699%
2/14/2025	Gilead Sciences Inc.	1,156,689	$2.46M	0.2%	N/A	0.552%
2/13/2025	Zacks Investment Management	480,874	$1.02M	0.0%	-6.9%	0.229%
2/13/2025	XTX Topco Ltd	158,537	$0.34M	0.0%	N/A	0.076%
2/13/2025	Barclays PLC	761,286	$1.62M	0.0%	+122.0%	0.363%
2/13/2025	Renaissance Technologies LLC	554,541	$1.18M	0.0%	-13.6%	0.264%
2/13/2025	Legal & General Group Plc	112,235	$0.24M	0.0%	-11.9%	0.054%
2/13/2025	Invesco Ltd.	127,486	$0.27M	0.0%	+7.0%	0.061%
2/13/2025	Cerity Partners LLC	387,387	$0.83M	0.0%	-10.4%	0.185%
2/13/2025	Wells Fargo & Company MN	104,593	$0.22M	0.0%	+29.4%	0.050%
2/12/2025	PAX Financial Group LLC	12,832	$27K	0.0%	N/A	0.006%
2/12/2025	RPO LLC	14,787	$31K	0.0%	N/A	0.007%
2/12/2025	JPMorgan Chase & Co.	3,736,132	$7.96M	0.0%	-8.6%	1.782%
2/12/2025	Mitsubishi UFJ Asset Management Co. Ltd.	253,576	$0.55M	0.0%	+7.1%	0.121%
2/11/2025	Vanguard Group Inc.	8,000,692	$17.04M	0.0%	-3.9%	3.816%
2/11/2025	KLP Kapitalforvaltning AS	20,400	$43K	0.0%	N/A	0.010%
2/11/2025	Sei Investments Co.	48,320	$0.10M	0.0%	N/A	0.023%
2/11/2025	American Century Companies Inc.	232,356	$0.50M	0.0%	+16.5%	0.111%
2/11/2025	Teacher Retirement System of Texas	43,877	$93K	0.0%	+28.9%	0.021%
2/11/2025	Intech Investment Management LLC	71,323	$0.15M	0.0%	+72.6%	0.034%
2/10/2025	Primecap Management Co. CA	4,927,340	$10.50M	0.0%	-13.1%	2.350%
2/10/2025	Cibc World Markets Corp	12,013	$26K	0.0%	N/A	0.006%
2/10/2025	Swiss National Bank	287,900	$0.61M	0.0%	+8.7%	0.137%
2/7/2025	HighTower Advisors LLC	12,150	$26K	0.0%	-59.0%	0.006%
2/6/2025	Charles Schwab Investment Management Inc.	1,188,838	$2.53M	0.0%	+0.8%	0.567%
2/4/2025	Bank of New York Mellon Corp	330,769	$0.71M	0.0%	+4.1%	0.158%
1/31/2025	Partners Capital Investment Group LLP	93,248	$0.20M	0.0%	-63.4%	0.044%
1/30/2025	Rhumbline Advisers	191,714	$0.41M	0.0%	+10.1%	0.091%
1/30/2025	Vontobel Holding Ltd.	195,457	$0.42M	0.0%	+788.4%	0.093%
1/24/2025	abrdn plc	364,382	$0.78M	0.0%	N/A	0.174%
1/17/2025	Bourgeon Capital Management LLC	118,700	$0.25M	0.0%	-16.7%	0.057%
1/6/2025	Nordea Investment Management AB	460,641	$0.99M	0.0%	+2.1%	0.220%
12/26/2024	JPMorgan Chase & Co.	4,087,506	$11.45M	0.0%	-0.9%	1.949%
11/25/2024	Tidal Investments LLC	142,747	$0.40M	0.0%	-39.7%	0.068%
11/19/2024	Barclays PLC	342,973	$0.96M	0.0%	+101.5%	0.164%
11/16/2024	Geode Capital Management LLC	3,227,104	$9.04M	0.0%	+14.4%	1.539%
11/15/2024	Barclays PLC	342,973	$0.96M	0.0%	+101.5%	0.164%
11/15/2024	MML Investors Services LLC	20,000	$56K	0.0%	N/A	0.010%
11/15/2024	Zacks Investment Management	516,601	$1.45M	0.0%	N/A	0.246%
11/15/2024	EP Wealth Advisors LLC	24,475	$69K	0.0%	+125.6%	0.012%
11/15/2024	State Street Corp	7,013,083	$19.64M	0.0%	-8.5%	3.345%
11/15/2024	Erste Asset Management GmbH	31,400	$91K	0.0%	N/A	0.015%
11/14/2024	Vestal Point Capital LP	1,500,000	$4.20M	0.3%	-31.8%	0.715%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	228,806	$0.64M	0.0%	-14.2%	0.109%
11/14/2024	MetLife Investment Management LLC	53,147	$0.15M	0.0%	-10.1%	0.025%
11/13/2024	BNP Paribas Financial Markets	46,374	$0.13M	0.0%	+541.5%	0.022%
11/13/2024	FMR LLC	30,026,956	$84.08M	0.0%	-3.9%	14.321%
11/13/2024	The Manufacturers Life Insurance Company	486,023	$1.36M	0.0%	+1.2%	0.232%
11/9/2024	Intech Investment Management LLC	41,331	$0.12M	0.0%	N/A	0.020%
11/6/2024	Cornercap Investment Counsel Inc.	28,533	$80K	0.0%	-55.0%	0.014%
11/6/2024	Curi RMB Capital LLC	149,577	$0.42M	0.0%	+47.5%	0.072%
10/25/2024	China Universal Asset Management Co. Ltd.	40,219	$0.11M	0.0%	+64.0%	0.019%
10/22/2024	Private Advisor Group LLC	12,087	$34K	0.0%	N/A	0.006%
10/11/2024	Creative Planning	61,396	$0.17M	0.0%	+108.7%	0.029%
10/10/2024	Exchange Traded Concepts LLC	60,675	$0.17M	0.0%	+25.5%	0.029%
10/3/2024	SG Americas Securities LLC	46,967	$0.13M	0.0%	+252.7%	0.022%
8/16/2024	Perceptive Advisors LLC	2,725,000	$6.35M	0.2%	N/A	1.304%
8/16/2024	Algert Global LLC	14,808	$35K	0.0%	N/A	0.007%
8/15/2024	Susquehanna Fundamental Investments LLC	418,699	$0.98M	0.0%	+46.2%	0.200%
8/15/2024	Lynx1 Capital Management LP	2,228,295	$5.19M	1.9%	N/A	1.066%
8/15/2024	The Manufacturers Life Insurance Company	480,381	$1.12M	0.0%	+70.3%	0.230%
8/15/2024	AQR Capital Management LLC	27,287	$64K	0.0%	N/A	0.013%
8/15/2024	Caxton Associates LP	466,110	$1.09M	0.0%	+8.1%	0.223%
8/14/2024	Squarepoint Ops LLC	126,628	$0.30M	0.0%	N/A	0.061%
8/14/2024	Profund Advisors LLC	76,160	$0.18M	0.0%	-37.1%	0.036%

Data available starting January 2016

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.61

$1.60

$1.75

50 Day Range

MA: $1.74

$1.36

$2.83

52 Week Range

Now: $1.61

$1.23

$3.78

Volume

2,178,832 shs

Average Volume

3,202,669 shs

Market Capitalization

$349.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Who are the company insiders with the largest holdings of Allogene Therapeutics?: Allogene Therapeutics' top insider shareholders include:
David D Chang (CEO)
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Earl Martin Douglas (SVP)
Zachary Roberts (EVP)
Franz B Humer (Director)
Timothy L Moore (Insider)
Benjamin Machinas Beneski (SVP)
Deborah M Messemer (Director)
Stephen Mayo (Director)
Learn More about top insider investors at Allogene Therapeutics.
Who are the major institutional investors of Allogene Therapeutics?: Allogene Therapeutics' top institutional shareholders include:
Rhumbline Advisers — 0.08%
Exchange Traded Concepts LLC — 0.03%
Wealth Enhancement Advisory Services LLC — 0.01%
Learn More about top institutional investors of Allogene Therapeutics stock.
Which institutional investors are selling Allogene Therapeutics stock?: During the previous quarter, ALLO stock was sold by these institutional investors:
Rhumbline Advisers
Within the previous year, company insiders that have sold Allogene Therapeutics company stock include:
David D Chang (CEO)
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Earl Martin Douglas (SVP)
Zachary Roberts (EVP)
Franz B Humer (Director)
Timothy L Moore (Insider)
Benjamin Machinas Beneski (SVP)
Learn More investors selling Allogene Therapeutics stock.
Which institutional investors are buying Allogene Therapeutics stock?: During the previous quarter, ALLO stock was acquired by institutional investors including:
Wealth Enhancement Advisory Services LLC
Exchange Traded Concepts LLC
Within the previous year, these company insiders have bought Allogene Therapeutics stock:
David D Chang (CEO)
Arie Belldegrun (Director)
Learn More investors buying Allogene Therapeutics stock.